全文获取类型
收费全文 | 113926篇 |
免费 | 7957篇 |
国内免费 | 4822篇 |
专业分类
耳鼻咽喉 | 578篇 |
儿科学 | 2090篇 |
妇产科学 | 1359篇 |
基础医学 | 18324篇 |
口腔科学 | 2437篇 |
临床医学 | 9102篇 |
内科学 | 18786篇 |
皮肤病学 | 1638篇 |
神经病学 | 10691篇 |
特种医学 | 1927篇 |
外国民族医学 | 18篇 |
外科学 | 7029篇 |
综合类 | 18233篇 |
现状与发展 | 23篇 |
预防医学 | 6194篇 |
眼科学 | 1221篇 |
药学 | 15458篇 |
16篇 | |
中国医学 | 3770篇 |
肿瘤学 | 7811篇 |
出版年
2023年 | 1069篇 |
2022年 | 1903篇 |
2021年 | 3636篇 |
2020年 | 3054篇 |
2019年 | 3187篇 |
2018年 | 3005篇 |
2017年 | 3173篇 |
2016年 | 3407篇 |
2015年 | 3842篇 |
2014年 | 6449篇 |
2013年 | 7368篇 |
2012年 | 6780篇 |
2011年 | 7749篇 |
2010年 | 6359篇 |
2009年 | 6183篇 |
2008年 | 6407篇 |
2007年 | 6225篇 |
2006年 | 5637篇 |
2005年 | 5055篇 |
2004年 | 4382篇 |
2003年 | 3854篇 |
2002年 | 3015篇 |
2001年 | 2706篇 |
2000年 | 2353篇 |
1999年 | 2090篇 |
1998年 | 1793篇 |
1997年 | 1574篇 |
1996年 | 1343篇 |
1995年 | 1081篇 |
1994年 | 1008篇 |
1993年 | 836篇 |
1992年 | 718篇 |
1991年 | 658篇 |
1990年 | 554篇 |
1989年 | 481篇 |
1988年 | 411篇 |
1987年 | 398篇 |
1986年 | 374篇 |
1985年 | 847篇 |
1984年 | 974篇 |
1983年 | 710篇 |
1982年 | 738篇 |
1981年 | 655篇 |
1980年 | 534篇 |
1979年 | 445篇 |
1978年 | 333篇 |
1977年 | 258篇 |
1976年 | 272篇 |
1975年 | 254篇 |
1974年 | 209篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Daisuke Ishibashi Takeshi Ishikawa Satoshi Mizuta Hiroya Tange Takehiro Nakagaki Tsuyoshi Hamada Noriyuki Nishida 《Neurotherapeutics》2020,17(4):1836
The accumulation of abnormal prion protein (PrPSc) produced by the structure conversion of PrP (PrPC) in the brain induces prion disease. Although the conversion process of the protein is still not fully elucidated, it has been known that the intramolecular chemical bridging in the most fragile pocket of PrP, known as the “hot spot,” stabilizes the structure of PrPC and inhibits the conversion process. Using our original structure-based drug discovery algorithm, we identified the low molecular weight compounds that predicted binding to the hot spot. NPR-130 and NPR-162 strongly bound to recombinant PrP in vitro, and fragment molecular orbital (FMO) analysis indicated that the high affinity of those candidates to the PrP is largely dependent on nonpolar interactions, such as van der Waals interactions. Those NPRs showed not only significant reduction of the PrPSc levels but also remarkable decrease of the number of aggresomes in persistently prion-infected cells. Intriguingly, treatment with those candidate compounds significantly prolonged the survival period of prion-infected mice and suppressed prion disease-specific pathological damage, such as vacuole degeneration, PrPSc accumulation, microgliosis, and astrogliosis in the brain, suggesting their possible clinical use. Our results indicate that in silico drug discovery using NUDE/DEGIMA may be widely useful to identify candidate compounds that effectively stabilize the protein.Electronic supplementary materialThe online version of this article (10.1007/s13311-020-00903-9) contains supplementary material, which is available to authorized users. 相似文献
22.
23.
24.
25.
26.
27.
28.
29.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献